drugset / Trial / NCT01912274

Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT01912274

Phase 2 Completed 50 enrolled Helsinn Healthcare SA
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and effectiveness of pracinostat when combined with azacitadine for patients who are 65 years of age or older and have Acute Myelogenous Leukemia (AML)

Timeline

Start
2013-12-24
Primary completion
2016-11-08
Completion
2016-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 75 mg/m2 Subcutaneous
Subject Pracinostat Other / unclassified 60 mg Oral